Sequencing Assay for Variant rs114518452: Clinical Trials

2 recruiting. 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	2	Recruiting 2

Follow Sequencing Assay for Variant rs114518452: new trials by email Literature Review of Sequencing Assay for Variant rs114518452 trials Research Report on Sequencing Assay for Variant rs114518452

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452 - Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)	Phase 1	Recruiting	Daniel Bauer	5	2026-08-01	2026-10-21
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452 - Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)	Phase 1	Recruiting	Daniel Bauer	10	2025-12-01	2026-02-03

Conditions studied

Anemia, Sickle Cell (2)  ·  beta-Thalassemia (1)

Sponsors

Daniel Bauer (2)

Countries

United States (2)